Company Description
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally.
It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.
The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories.
It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors.
IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Country | United States |
IPO Date | Jul 16, 2014 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 148 |
CEO | Roger E. Susi |
Contact Details
Address: 1025 Willa Springs Dr. Winter Springs, Florida 32708 United States | |
Phone | (407) 677-8022 |
Website | iradimed.com |
Stock Details
Ticker Symbol | IRMD |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001325618 |
CUSIP Number | 46266A109 |
ISIN Number | US46266A1097 |
Employer ID | 73-1408526 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Roger E. Susi | Founder, Chairman, Chief Executive Officer and President |
John F. Glenn | Chief Financial Officer and Corporate Secretary |
Randy Waddell | Vice President of Worldwide Sales and Marketing |
Steve Kachelmeyer | Vice President of Regulatory Affairs and Quality Assurance |
Lynn Neuhardt | Vice President of Research and Development |
Chris Williamson | Executive Vice President of Continuous Improvement and Information Technology |
Matt Garner | Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 20, 2024 | 8-K | Current Report |
Jun 7, 2024 | 8-K | Current Report |
Jun 3, 2024 | 144 | Filing |
Jun 3, 2024 | 8-K | Current Report |
May 9, 2024 | ARS | Filing |
May 8, 2024 | EFFECT | Notice of Effectiveness |
May 6, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
May 3, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
May 2, 2024 | 10-Q | Quarterly Report |
May 2, 2024 | 8-K | Current Report |